A randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma.
To assess the effectiveness of IV and nebulised magnesium sulphate in the treatment of acute severe asthma.
Multi centre randomised controlled trial of intravenous (IV) or nebulised magnesium sulphate versus placebo for acute severe asthma
Professor Steve Goodacre
Professor Alasdair Gray
S Goodacre, J Cohen, M Bradburn, A Gray, J Benger, T Coats on behalf of the 3Mg Research Team. The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for severe acute asthma. The Lancet Respiratory Medicine. (2013); 1:293 – 300.
Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, et al. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. . Health Technology Assessment. (2014);18(22).
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.